Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1910–1913. doi: 10.1128/aac.40.8.1910

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

J R Perfect 1, G M Cox 1, R K Dodge 1, W A Schell 1
PMCID: PMC163438  PMID: 8843302

Abstract

Multiple isolates of Cryptococcus neoformans were tested to compare the in vitro activity of a new triazole, SCH56592, with those of amphotericin B, fluconazole, and itraconazole, MICs of each drug were determined, and minimum fungicidal concentrations of SCH56592 and amphotericin B were measured. MICs of SCH56592 were lower than those of amphotericin B and fluconazole but not those of itraconazole. Minimum fungicidal concentrations of SCH56592 were lower than those of amphotericin B. SCH56592 in the presence of human serum produces an in vitro fungicidal effect for Cryptococcus neoformans. The data indicate that SCH56592 might exert fungicidal as well as inhibitory properties in vivo. On the basis of these results, SCH56592 was evaluated with a rabbit model of experimental cryptococcal meningitis; SCH56592 treatment was compared with treatment with fluconazole. Despite no detectable drug concentrations in the cerebrospinal fluid, the activity of SCH56592 against C. neoformans infection was equivalent to that of fluconazole. SCH56592 has potent in vitro activity against C. neoformans and compares favorably to treatment with fluconazole for a central nervous system infection. SCH56592 should be studied for use in humans with cryptococcal infections.

Full Text

The Full Text of this article is available as a PDF (172.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. E., Dismukes W. E., Duma R. J., Medoff G., Sande M. A., Gallis H., Leonard J., Fields B. T., Bradshaw M., Haywood H. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. doi: 10.1056/NEJM197907193010303. [DOI] [PubMed] [Google Scholar]
  2. Bozzette S. A., Larsen R. A., Chiu J., Leal M. A., Jacobsen J., Rothman P., Robinson P., Gilbert G., McCutchan J. A., Tilles J. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med. 1991 Feb 28;324(9):580–584. doi: 10.1056/NEJM199102283240902. [DOI] [PubMed] [Google Scholar]
  3. Denning D. W., Tucker R. M., Hanson L. H., Hamilton J. R., Stevens D. A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989 Oct;149(10):2301–2308. [PubMed] [Google Scholar]
  4. Nassar F., Brummer E., Stevens D. A. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob Agents Chemother. 1995 Nov;39(11):2490–2493. doi: 10.1128/aac.39.11.2490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Paugam A., Dupouy-Camet J., Blanche P., Gangneux J. P., Tourte-Schaefer C., Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis. 1994 Nov;19(5):975–976. doi: 10.1093/clinids/19.5.975-a. [DOI] [PubMed] [Google Scholar]
  6. Perfect J. R., Durack D. T. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother. 1985 Dec;28(6):751–755. doi: 10.1128/aac.28.6.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Perfect J. R., Durack D. T. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis. 1982 Sep;146(3):429–435. doi: 10.1093/infdis/146.3.429. [DOI] [PubMed] [Google Scholar]
  8. Perfect J. R., Lang S. D., Durack D. T. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol. 1980 Oct;101(1):177–194. [PMC free article] [PubMed] [Google Scholar]
  9. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Perfect J. R., Savani D. V., Durack D. T. Uptake of itraconazole by alveolar macrophages. Antimicrob Agents Chemother. 1993 Apr;37(4):903–904. doi: 10.1128/aac.37.4.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Perfect J. R., Wright K. A. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother. 1994 Jan;33(1):73–81. doi: 10.1093/jac/33.1.73. [DOI] [PubMed] [Google Scholar]
  12. Perfect J. R., Wright K. A., Hobbs M. M., Durack D. T. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother. 1989 Oct;33(10):1735–1740. doi: 10.1128/aac.33.10.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Powderly W. G., Finkelstein D., Feinberg J., Frame P., He W., van der Horst C., Koletar S. L., Eyster M. E., Carey J., Waskin H. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995 Mar 16;332(11):700–705. doi: 10.1056/NEJM199503163321102. [DOI] [PubMed] [Google Scholar]
  14. Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Grieco M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. F. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9;326(2):83–89. doi: 10.1056/NEJM199201093260202. [DOI] [PubMed] [Google Scholar]
  15. Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 1993 Aug;168(2):508–510. doi: 10.1093/infdis/168.2.508. [DOI] [PubMed] [Google Scholar]
  16. Viviani M. A., Tortorano A. M., Langer M., Almaviva M., Negri C., Cristina S., Scoccia S., De Maria R., Fiocchi R., Ferrazzi P. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect. 1989 Mar;18(2):151–165. doi: 10.1016/s0163-4453(89)91178-x. [DOI] [PubMed] [Google Scholar]
  17. Wright K. A., Perfect J. R., Ritter W. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother. 1990 Sep;26(3):387–397. doi: 10.1093/jac/26.3.387. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES